Neurocognitive Growth Charting in Psychosis Spectrum Youths

Abstract

IMPORTANCE Psychosis-risk studies have examined help-seeking adolescents and young adults. Population-based studies evaluating psychotic symptoms and neurocognitive performance across childhood are needed for "growth charting" cognitive development. We hypothesized that psychosis spectrum youths have delayed neurocognitive age relative to chronological age. We expected larger lags with increased symptom severity and in late adolescence and early adulthood.OBJECTIVES To examine neurocognitive age and compare typically developing participants with psychosis spectrum participants. DESIGN, SETTING, AND PARTICIPANTSThe Philadelphia Neurodevelopmental Cohort is a genotyped sample, with electronic medical records, enrolled in the study of brain behavior. In an academic and children's hospital health care network, a structured psychiatric evaluation was performed and a computerized neurocognitive battery administered to evaluate performance in several domains. From 18 344 youths in the recruitment pool who were aged 8 to 21 years, physically and cognitively capable of participating, and proficient in English, participants were randomly selected with stratification for age, sex, and ethnicity. A total of 9138 participants were enrolled in the study between November 1, 2009, and November 30, 2011, and 2321 endorsed psychotic symptoms: 1423 significant (psychosis spectrum) and 898 limited (psychosis limited). They had no comorbid medical conditions. They were compared with 981 participants endorsing significant other psychiatric symptoms and with 1963 typically developing children with no psychiatric or medical disorders. MAIN OUTCOMES AND MEASURESThe computerized neurocognitive battery provides accuracy and speed measures on 12 tests and speed measures alone on 2, yielding 26 measures used in a regression analysis to predict chronological age. Prediction was performed on the entire set and separately for each domain (executive, episodic memory, complex cognition, social cognition, and sensorimotor speed).RESULTS Throughout childhood and adolescence, the psychosis spectrum group had lower predicted age compared with the typically developing group and the group with other psychiatric symptoms. The psychosis spectrum group had a greater developmental lag than the psychosis limited group. The lags were most pronounced for complex cognition and social cognition and were smallest for sensorimotor speed.CONCLUSIONS AND RELEVANCE Individuals who endorse psychotic symptoms are neurocognitively delayed across the age range; this delay relates to symptom severity and is not prominent in other psychiatric disorders. Combined clinical and neurocognitive assessment can facilitate early detection and targeted intervention to delay or ameliorate disease progression.

Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study

“…45 Another study which assessed negative subthreshold psychotic symptoms in typically developing youths found significant associations with the participants' neurocognitive performance and functions that are central to the evolution of psychosis. 46 Taken together, the accumulating evidence suggest that 22q11.2DS individuals with subthreshold negative symptoms in our study are at higher risk of transitioning into full-blown psychotic disorders.…”

Oscillations and Neuronal Dynamics in Schizophrenia: The Search for Basic Symptoms and Translational Opportunities

“…Cognitive impairments across several domains are detectable several years before the onset of psychosis [93] which typically emerges during late adolescence/early adulthood. One possibility therefore is that the onset of clinically manifested symptoms during this developmental period is due to the ongoing changes in oscillatory dynamics and the underlying neurobiological mechanisms responsible for coherent mental states.…”

Comorbidity of Physical and Mental Disorders in the Neurodevelopmental Genomics Cohort Study

“…27,28 The Center of Applied Genomics identified the sample through pediatric clinics within the CHOP health care network. Their team enrolled and genotyped 50 293 children who provided written informed consent/assent authorizing access to EMRs and to be recontacted for future studies.…”